Stocks · News reference
Roivant Sciences announced it will release its financial results for the second fiscal quarter ended September 30, 2026, on November 9, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Roivant Sciences and its subsidiary Priovant Therapeutics reported that the Phase 3 CLARITY program for brepocitinib met primary and key secondary endpoints in patients with non-infectious uveitis.
Roivant and Priovant announced positive Phase 3 results for brepocitinib in treating non-infectious uveitis. The drug met primary and secondary endpoints in both CLARITY-1 and CLARITY-2 trials, with 62% of patients achieving steroid-free quiescence at Week 48 compared to 20% on placebo. The companies plan to file a supplemental New Drug Application in the first half of 2027.
Immunovant announced it will report financial results for the second fiscal quarter ended September 30, 2026 on November 9, 2026, with a conference call hosted by majority stockholder Roivant Sciences. The company is a clinical-stage immunology firm developing anti-FcRn targeted therapies for autoimmune diseases, with ongoing clinical studies in Graves' disease, myasthenia gravis, and CIDP.